Processa Pharmaceuticals (PCSA) Research & Development (2012 - 2026)

Processa Pharmaceuticals (PCSA) has reported Research & Development for 15 consecutive years, with $649877.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 73.44% year-over-year to $649877.0; the trailing twelve-month figure through Jun 2026 stood at $6.2 million (down 22.42% YoY), and the FY2025 full-year result was $7.8 million, up 7.45% from the prior year.
• Research & Development slipped to $649877.0 in Q2 2026 per PCSA's latest filing, from $1.8 million in the prior quarter.
• Across five years, Research & Development topped out at $3.2 million in Q4 2022 and bottomed at $649877.0 in Q2 2026.
• Historically, Research & Development has averaged $1.9 million across 5 years, with a median of $1.7 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Research & Development soared 98.61% in 2024, then tumbled 73.44% in 2026.
• Over 5 years, Research & Development stood at $3.2 million in 2022, then sank by 58.39% to $1.3 million in 2023, then gained by 29.66% to $1.7 million in 2024, then increased by 23.43% to $2.1 million in 2025, then plunged by 69.25% to $649877.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $649877.0, $1.8 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.